相关实验视频

Updated: May 8, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

黄昏:一个随机试验的单一治疗Ticagrelor对Ticagrelor加阿司匹林开始在3个月的高风险患者接受皮肤冠状动脉干预

Johny Nicolas¹, Usman Baber¹, Roxana Mehran¹

¹The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York City, NY.

|December 25, 2024

概括

在3个月的双重抗血小板治疗后,将高风险患者转换为蒂卡格勒罗单疗法显著减少了出血事件. 这一策略保持了类似的缺血事件率,为穿皮冠状动脉干预后提供了更安全的方法.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.

背景情况:

通过皮肤冠状动脉干预 (PCI) 后,用阿司匹林和P2Y12抑制剂进行双重抗血小板治疗 (DAPT) 是标准的.
患有高出血风险的DAPT患者经历出血并发症的增加.
目前正在探索P2Y12抑制剂单疗法,以减轻出血风险.

研究的目的:

在PCI后的高风险患者中,评估特卡格勒罗单疗法与特卡格勒罗加阿司匹林的疗效和安全性.
为了确定是否过渡到单一疗法可以减少出血事件而不会增加缺血事件.

主要方法:

在DAPT治疗3个月后,TWILIGHT试验随机分配了7,119名高风险患者,接受格勒罗加安慰剂或格勒罗加阿司匹林.
患者继续治疗12个月.
主要终点是学术研究联盟 (BARC) 的2,3或5型出血;次要终点是缺血事件.

主要成果:

与DAPT (HR 0.56; p<0.001) 相比,单独使用蒂卡格勒治疗显著减少了BARC 2,3,或5次出血事件 (HR 0.56; p<0.001).
在单一治疗和DAPT手臂 (HR 0.99) 中,缺血事件的发生率相似.
在单一治疗中没有观察到死亡,心肌梗塞或中风的显著增加.

结论:

经过短时间的DAPT治疗后,单独使用蒂卡格勒是PCI后高风险患者的安全有效策略.
这种方法可以降低出血风险,而不会影响对缺血事件的保护.
P2Y12抑制剂单疗是优化特定患者群体抗血小板治疗的有价值选择.

关键词:

亚司匹林是一种阿司匹林.黄昏之光在黄昏之光流血出血流血出血药物释放的支架可以释放药物.双重抗血小板疗法双重抗血小板疗法这就是Ticagrelor.

更多相关视频

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...